CN112437765A - 贝派地酸的盐形式及其使用方法 - Google Patents

贝派地酸的盐形式及其使用方法 Download PDF

Info

Publication number
CN112437765A
CN112437765A CN202080003148.4A CN202080003148A CN112437765A CN 112437765 A CN112437765 A CN 112437765A CN 202080003148 A CN202080003148 A CN 202080003148A CN 112437765 A CN112437765 A CN 112437765A
Authority
CN
China
Prior art keywords
degrees
compound
formula
crystalline
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080003148.4A
Other languages
English (en)
Chinese (zh)
Inventor
R.科普
M.阿布德尔纳瑟
C.M.西马鲁斯蒂
C.刘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esperion Therapeutics Inc
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71528020&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN112437765(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of CN112437765A publication Critical patent/CN112437765A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/04—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid halides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/285—Polyhydroxy dicarboxylic acids having five or more carbon atoms, e.g. saccharic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/347—Saturated compounds containing more than one carboxyl group containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/307—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/31—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/313—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of doubly bound oxygen containing functional groups, e.g. carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080003148.4A 2019-06-21 2020-06-19 贝派地酸的盐形式及其使用方法 Pending CN112437765A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962864873P 2019-06-21 2019-06-21
US62/864,873 2019-06-21
PCT/US2020/038624 WO2020257573A1 (en) 2019-06-21 2020-06-19 Salt forms of bempedoic acid and methods for using the same

Publications (1)

Publication Number Publication Date
CN112437765A true CN112437765A (zh) 2021-03-02

Family

ID=71528020

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202080003150.1A Pending CN112437766A (zh) 2019-06-21 2020-06-19 制备贝派地酸及其组合物的方法
CN202211022415.XA Pending CN115429784A (zh) 2019-06-21 2020-06-19 制备贝派地酸及其组合物的方法
CN202080003148.4A Pending CN112437765A (zh) 2019-06-21 2020-06-19 贝派地酸的盐形式及其使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202080003150.1A Pending CN112437766A (zh) 2019-06-21 2020-06-19 制备贝派地酸及其组合物的方法
CN202211022415.XA Pending CN115429784A (zh) 2019-06-21 2020-06-19 制备贝派地酸及其组合物的方法

Country Status (13)

Country Link
US (10) US12344578B2 (enExample)
EP (3) EP3986860A1 (enExample)
JP (3) JP2022537049A (enExample)
KR (3) KR20220024816A (enExample)
CN (3) CN112437766A (enExample)
AU (3) AU2020295503A1 (enExample)
BR (2) BR112021025928A2 (enExample)
CA (2) CA3144372A1 (enExample)
ES (1) ES3032779T3 (enExample)
HU (1) HUE072061T2 (enExample)
IL (3) IL288909A (enExample)
MX (2) MX2021015936A (enExample)
WO (2) WO2020257571A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115504914A (zh) * 2021-06-23 2022-12-23 武汉武药科技有限公司 一种贝派地酸中间体的制备方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3144372A1 (en) 2019-06-21 2020-12-24 Esperion Therapeutics, Inc. Salt forms of bempedoic acid and methods for using the same
EP4038045A1 (en) 2019-10-03 2022-08-10 Synthon B.V. Crystalline forms of bempedoic acid
WO2021110929A1 (en) * 2019-12-06 2021-06-10 Synthon B.V. Crystalline forms of sodium salt of bempedoic acid
CN111559961A (zh) * 2020-05-26 2020-08-21 杭州科巢生物科技有限公司 一种贝派地酸晶型及其制备方法
WO2021255180A1 (en) * 2020-06-19 2021-12-23 Synthon B.V. Salts of bempedoic acid
CN112521282A (zh) * 2020-12-02 2021-03-19 苏州汉德创宏生化科技有限公司 一种贝派地酸中间体及其合成方法
WO2022149161A1 (en) * 2021-01-05 2022-07-14 Dr. Reddy's Laboratories Limited Process for preparation of bempedoic acid and its intermediates
US20240366625A1 (en) 2021-06-02 2024-11-07 Esperion Therapeutics, Inc. Compositions containing and therapies using bempedoic acid and tolvaptan
CN114436837B (zh) * 2021-12-27 2024-02-20 甘李药业股份有限公司 一种贝派地酸中间体的纯化方法
WO2023187833A1 (en) * 2022-03-30 2023-10-05 Enaltec Labs Private Limited A novel salt of bempedoic acid
WO2024151311A1 (en) 2023-01-09 2024-07-18 Esperion Therapeutics, Inc. Methods of treatment using bempedoic acid
CN116589341A (zh) * 2023-04-14 2023-08-15 苏州汉德创宏生化科技有限公司 一种抗高血酯药物中间体的制备方法
WO2025196153A1 (en) 2024-03-20 2025-09-25 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
WO2025196154A1 (en) 2024-03-20 2025-09-25 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
WO2025196155A1 (en) 2024-03-20 2025-09-25 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
WO2025238159A1 (en) 2024-05-16 2025-11-20 Astrazeneca Ab Combination therapy comprising azd0780 and ezetimibe

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067489A2 (en) * 2003-01-23 2004-08-12 Esperion Therapeutics, Inc. Hydroxyl compounds and compositions for cholesterol management and related uses
US20140256809A1 (en) * 2013-02-19 2014-09-11 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
WO2015018060A1 (en) * 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
WO2018218147A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
CN109721486A (zh) * 2017-10-31 2019-05-07 鲁南制药集团股份有限公司 一种8-羟基-2,2,14,14-四甲基-十五烷二酸的合成方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152148A (en) 1963-01-03 1964-10-06 Dow Chemical Co Preparation of comenic and pyromeconic acids
US3441605A (en) 1965-02-17 1969-04-29 Wallace & Tiernan Inc Diketo-dicarboxylic acids and salts and preparation thereof by alkaline oxidation
GB1196595A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of a Lactone
GB1196598A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of a Ketosebacic Acid
GB1196594A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Improvements in and relating to the production of Sebacic Acid
FR1545224A (fr) 1966-12-21 1968-11-08 Geigy Ag J R Procédé de préparation de l'acide sébacique
GB1196597A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of an Oxido-Cyclodecene
GB1196596A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of a hydroxysebacic acid
US3773946A (en) 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
US3930024A (en) 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4281200A (en) 1979-08-30 1981-07-28 The Dow Chemical Company Catalytic process for converting oxazolidinones to their corresponding aminoalcohols
JPS5639033A (en) 1979-09-04 1981-04-14 Kao Corp Alpha-mono(methyl-branched alkyl glyceryl ether and skin cosmetic containing the same
IL64542A0 (en) 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
IT1164254B (it) 1983-05-30 1987-04-08 Luso Farmaco Inst 3-(3-idrossibutossi)-1-butanolo e suo metodo di preparazione
JPS59232811A (ja) 1983-06-16 1984-12-27 Sumitomo Chem Co Ltd 芳香族ポリアミドイミド樹脂成形体の製造方法
JPS60136512A (ja) 1983-12-26 1985-07-20 Eisai Co Ltd 脂質代謝改善剤
DE3423166A1 (de) 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US4896344A (en) 1984-10-15 1990-01-23 Grady John K X-ray video system
US4634119A (en) 1985-07-11 1987-01-06 Pesthy Paul K Resilient exercise machine with body support platform
US4714762A (en) 1986-10-31 1987-12-22 Warner-Lambert Company Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5428062A (en) 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US4758880A (en) 1987-03-27 1988-07-19 The Grass Valley Group, Inc. Video matte generator
JP2999579B2 (ja) 1990-07-18 2000-01-17 武田薬品工業株式会社 Ｄｎａおよびその用途
US5254589A (en) 1991-10-15 1993-10-19 Warner-Lambert Company Sulfonyl urea and carbamate ACAT inhibitors
IL109431A (en) 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US5420339A (en) 1993-11-22 1995-05-30 Warner-Lambert Company Alpha-aryl or heteroaryl-substituted amide ester ACAT inhibitors
JP2937012B2 (ja) 1994-04-08 1999-08-23 時久 増田 角筒包装袋の製造方法及び装置
US5578639A (en) 1994-07-01 1996-11-26 Warner-Lambert Company PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
US5504073A (en) 1994-07-01 1996-04-02 Warner-Lambert Company PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
SK284142B6 (sk) 1995-11-02 2004-10-05 Warner-Lambert Company Farmaceutická kompozícia na reguláciu koncentrácie lipidov, stabilizáciu aterosklerotických lézií a na prevenciu pretrhnutia aterosklerotického plaku
JP4139448B2 (ja) 1996-08-13 2008-08-27 信越化学工業株式会社 α−ブロモ，ω−クロロアルカンの製造方法
US5807846A (en) 1996-11-14 1998-09-15 Warner-Lambert Company Phosphonamide ACAT inhibitors
IL119971A (en) 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
US6093744A (en) 1997-04-21 2000-07-25 Warner-Lambert Company N-acyl sulfamic acid esters useful as hypocholesterolemic agents
IL121165A0 (en) 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6362236B1 (en) 1997-11-25 2002-03-26 Warner-Lambert Company Inhibition of lipoprotein oxidation
JP2002541129A (ja) 1999-04-01 2002-12-03 エスペリオン セラピューティクス インコーポレイテッド エーテル化合物、組成物、およびそれらの使用
AU2002213136B2 (en) 2000-10-11 2007-01-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US6703422B2 (en) 2000-10-11 2004-03-09 Esperion Therapeutics, Inc. Sulfide and disulfide compounds and compositions for cholesterol management and related uses
US7304093B2 (en) 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US6713507B2 (en) 2000-10-11 2004-03-30 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
CN1479721A (zh) 2000-10-11 2004-03-03 ͨ��ҽ�ƹ�˾ 用于胆固醇治疗和相关应用的亚砜和双亚砜化合物和组合物
US7053046B2 (en) 2001-12-21 2006-05-30 Mcgrath Kevin Peptide activators of VEGF
EP1701931B1 (en) 2003-12-24 2018-10-10 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
JP4553181B2 (ja) 2004-03-25 2010-09-29 株式会社サタケ 残留農薬分析方法
US8209479B2 (en) 2007-07-18 2012-06-26 Google Inc. Memory circuit system and method
WO2013103842A1 (en) 2012-01-06 2013-07-11 Michigan Life Therapeutics, Llc Methods of reducing risk of cardiovascular disease
US20160058751A1 (en) 2013-03-28 2016-03-03 Cellworks Group, Inc. Composition and method for treating cancer
MA42616A (fr) 2015-03-13 2021-05-19 Esperion Therapeutics Inc Combinaisons et formulations de doses fixes comprenant etc1002 et ézétimibe, et procédés de traitement ou de réduction du risque de maladie cardio-vasculaire
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2017023165A1 (en) 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator
WO2018148417A1 (en) 2017-02-08 2018-08-16 Esperion Therapeutics, Inc. Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease
TW201906599A (zh) 2017-05-11 2019-02-16 美商珍費爾醫療公司 吉卡賓組成物及其使用方法
CN107628975B (zh) * 2017-09-17 2019-10-29 贵州医科大学 赖氨酸衍生物类组蛋白去乙酰化酶抑制剂及其合成和应用
WO2019161307A1 (en) 2018-02-16 2019-08-22 Esperion Therapeutics, Inc. Sustained release formulations of bempedoic acid
EP3666750A1 (en) * 2018-12-10 2020-06-17 Sandoz AG Crystalline form of bempedoic acid
JP2022516530A (ja) * 2018-12-31 2022-02-28 ルピン・リミテッド ベンペド酸の新規塩及び多形体
CA3144372A1 (en) 2019-06-21 2020-12-24 Esperion Therapeutics, Inc. Salt forms of bempedoic acid and methods for using the same
WO2021110929A1 (en) * 2019-12-06 2021-06-10 Synthon B.V. Crystalline forms of sodium salt of bempedoic acid
WO2022149161A1 (en) 2021-01-05 2022-07-14 Dr. Reddy's Laboratories Limited Process for preparation of bempedoic acid and its intermediates

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067489A2 (en) * 2003-01-23 2004-08-12 Esperion Therapeutics, Inc. Hydroxyl compounds and compositions for cholesterol management and related uses
US20140256809A1 (en) * 2013-02-19 2014-09-11 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
WO2015018060A1 (en) * 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
WO2018218147A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
CN109721486A (zh) * 2017-10-31 2019-05-07 鲁南制药集团股份有限公司 一种8-羟基-2,2,14,14-四甲基-十五烷二酸的合成方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MINO R. CAIRA ET AL.: "Crystalline Polymorphism of Organic Compounds", 《TOPICS IN CURRENT CHEMISTRY》, vol. 198, pages 163 - 208, XP008166276, DOI: 10.1007/3-540-69178-2_5 *
STEPHEN BYRN ET AL.: "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", 《PHARMACEUTICAL RESEARCH》, vol. 12, no. 7, pages 945 - 954, XP055399407, DOI: 10.1023/A:1016241927429 *
吕扬 等: "《晶型药物》", vol. 1, 人民卫生出版社, pages: 6 - 7 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115504914A (zh) * 2021-06-23 2022-12-23 武汉武药科技有限公司 一种贝派地酸中间体的制备方法
CN115504914B (zh) * 2021-06-23 2024-05-07 武汉武药科技有限公司 一种贝派地酸中间体的制备方法

Also Published As

Publication number Publication date
US20230141635A1 (en) 2023-05-11
WO2020257571A1 (en) 2020-12-24
WO2020257573A1 (en) 2020-12-24
US12344578B2 (en) 2025-07-01
JP2025032197A (ja) 2025-03-11
EP4438114A2 (en) 2024-10-02
US20240182396A1 (en) 2024-06-06
HUE072061T2 (hu) 2025-10-28
JP2022536979A (ja) 2022-08-22
US20240317665A1 (en) 2024-09-26
US11407705B2 (en) 2022-08-09
US12404227B2 (en) 2025-09-02
KR20220024815A (ko) 2022-03-03
CN115429784A (zh) 2022-12-06
AU2020296094B2 (en) 2025-02-06
US20220281795A1 (en) 2022-09-08
US11613511B2 (en) 2023-03-28
US20230183160A1 (en) 2023-06-15
US11926584B2 (en) 2024-03-12
EP3986859B1 (en) 2025-04-30
CA3144372A1 (en) 2020-12-24
MX2021015936A (es) 2022-04-26
US20240286987A1 (en) 2024-08-29
AU2020296094A1 (en) 2022-01-27
CA3144371A1 (en) 2020-12-24
US20210139401A1 (en) 2021-05-13
AU2025203232A1 (en) 2025-05-29
JP2022537049A (ja) 2022-08-23
US20220388937A1 (en) 2022-12-08
BR112021025964A2 (pt) 2022-05-24
KR20220024816A (ko) 2022-03-03
IL324076A (en) 2025-12-01
IL288909A (en) 2022-02-01
ES3032779T3 (en) 2025-07-24
US11987548B2 (en) 2024-05-21
US12398087B2 (en) 2025-08-26
US11760714B2 (en) 2023-09-19
US20210139405A1 (en) 2021-05-13
AU2020295503A1 (en) 2022-01-27
EP3986860A1 (en) 2022-04-27
BR112021025928A2 (pt) 2022-05-10
EP3986859A1 (en) 2022-04-27
US20230250043A1 (en) 2023-08-10
IL288997A (en) 2022-02-01
MX2021015935A (es) 2022-04-26
KR20250143358A (ko) 2025-10-01
CN112437766A (zh) 2021-03-02
EP4438114A3 (en) 2024-12-25

Similar Documents

Publication Publication Date Title
CN112437765A (zh) 贝派地酸的盐形式及其使用方法
EP3337800B1 (de) Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxamid und dessen aufreinigung für die verwendung als pharmazeutischer wirkstoff
EP2343296A1 (en) A process for the purification of paliperidone
JP2014534208A5 (enExample)
WO2005030698A1 (en) Process for the preparation of voglibose
HK40117856A (en) Methods of making bempedoic acid and compositions of the same
HK40071684A (en) Methods of making bempedoic acid
HK40071684B (en) Methods of making bempedoic acid
EA046484B1 (ru) Способы получения бемпедоевой кислоты
HK40035594A (en) Novel calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferatory agents
HK40035594B (en) Novel calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferatory agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210302

WD01 Invention patent application deemed withdrawn after publication